- Report
- October 2023
- 190 Pages
Global
From €4017EUR$4,500USD£3,493GBP
- Report
- June 2023
- 112 Pages
Global
From €4017EUR$4,500USD£3,493GBP
- Report
- May 2022
- 70 Pages
Global
From €2232EUR$2,500USD£1,940GBP
- Report
- July 2024
- 185 Pages
Global
From €2232EUR$2,500USD£1,940GBP
- Report
- May 2024
- 174 Pages
Global
From €2232EUR$2,500USD£1,940GBP
- Report
- October 2021
- 288 Pages
Global
From €3214EUR$3,600USD£2,794GBP
- Report
- July 2024
- 200 Pages
Global
From €4418EUR$4,949USD£3,841GBP
- Report
- February 2024
- 140 Pages
Global
From €4436EUR$4,969USD£3,857GBP
- Report
- April 2023
- 147 Pages
Global
From €4418EUR$4,949USD£3,841GBP
- Report
- April 2023
- 147 Pages
Global
From €4418EUR$4,949USD£3,841GBP
- Report
- April 2023
- 147 Pages
Global
From €4418EUR$4,949USD£3,841GBP
- Report
- July 2024
- 200 Pages
Global
From €4418EUR$4,949USD£3,841GBP
- Report
- February 2023
- 48 Pages
Global
From €3566EUR$3,995USD£3,101GBP
- Newsletter
- October 2025
- 2 Pages
Global
From €117EUR$131USD£102GBP
- Report
- June 2024
- 200 Pages
Global
From €4459EUR$4,995USD£3,877GBP
- Report
- October 2023
- 85 Pages
United States
From €4330EUR$4,850USD£3,765GBP
- Report
- July 2023
- 200 Pages
Global
From €4017EUR$4,500USD£3,493GBP
- Report
- July 2023
- 218 Pages
Global
From €4017EUR$4,500USD£3,493GBP
- Report
- August 2019
- 42 Pages
Global
€2674EUR$2,995USD£2,325GBP
- Report
- August 2018
- 21 Pages
Global
From €8927EUR$10,000USD£7,762GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more